Glenmark Pharmaceuticals Inc., USA (Glenmark) has announced the official launch of Olanzapine for Injection, 10mg/vial, available as a Single-Dose Vial.
The newly launched product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Zyprexa® IntraMuscular Injection (10mg}/vial, from CheplapharmRegistration GmbH. According to IQVIA® sales data for the 12-month period ending May 2026, the Zyprexa® IntraMuscularInjection market generated annual sales of approximately $25.4 million.
“The launch of Olanzapine for Injection underscores our strategic focus on growing a robust injectables portfolio and strengthening our presence within the institutional channel,” said Marc Kikuchi, President & Business Head, North America. “It reflects our continued commitment to expanding access to quality and affordable treatment options to meet the evolving needs of patients and healthcare providers.”
Glenmark’s Olanzapine for Injection is commercialized strictly for the indications detailed in its approved product labeling. The launch aligns with parent company Glenmark Pharmaceuticals Ltd.’s global vision of leveraging research and innovation to elevate accessibility to high-quality healthcare.
Written by: Pragna Biswas
Graphics by: Pramit Hazra
